Przejdź do zawartości
Merck

Bacterial expression of human kynurenine 3-monooxygenase: solubility, activity, purification.

Protein expression and purification (2013-12-10)
K Wilson, D J Mole, M Binnie, N Z M Homer, X Zheng, B A Yard, J P Iredale, M Auer, S P Webster
ABSTRAKT

Kynurenine 3-monooxygenase (KMO) is an enzyme central to the kynurenine pathway of tryptophan metabolism. KMO has been implicated as a therapeutic target in several disease states, including Huntington's disease. Recombinant human KMO protein production is challenging due to the presence of transmembrane domains, which localise KMO to the outer mitochondrial membrane and render KMO insoluble in many in vitro expression systems. Efficient bacterial expression of human KMO would accelerate drug development of KMO inhibitors but until now this has not been achieved. Here we report the first successful bacterial (Escherichia coli) expression of active FLAG™-tagged human KMO enzyme expressed in the soluble fraction and progress towards its purification.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
L-Kynurenine, ≥98% (HPLC)
Sigma-Aldrich
Ethylenediaminetetraacetic acid, ACS reagent, 99.4-100.6%, powder
Sigma-Aldrich
Isopropyl β-D-1-thiogalactopyranoside, ≥99% (TLC)
Sigma-Aldrich
ANTI-FLAG® M2 antibody, Mouse monoclonal, 1 mg/mL, clone M2, affinity isolated antibody, buffered aqueous solution (50% glycerol, 10 mM sodium phosphate, and 150 mM NaCl, pH 7.4)
Sigma-Aldrich
Flavin adenine dinucleotide disodium salt hydrate, ≥95% (HPLC), powder
Sigma-Aldrich
n-Dodecyl β-D-maltoside, ≥98% (GC)
Roche
Koktajl inhibitorów proteazy , Tablets provided in EASYpacks